in the correspondingly lower doses required. Figure 18.14 illustrates an instance

demonstrating the distinct pharmacokinetic superiority in rate as well as extent of its

systemic bioavailability of the phospholipid-based NLC formulation of a plant

bioactive, mangiferin, developed at our end as per FbD approach (Khurana et al.

2017).

Several hundreds of industrial and academic scientists of India, Canada, Taiwan

and Bangladesh have been trained on such industrially pragmatic and federally

essential

paradigms

of

QbD

and

nanomedicines

through

on-site

training

programmes, seminars and conference workshops. The pictorial collage in

Fig. 18.15 portrays some of the logos of industrial houses with which industry-

academia interactions have taken place, primarily for their industrial training on

QbD paradigms. Concerted contributions as a pioneering torchbearer and persistent

crusader entirely in the domain of QbD-enabled drug delivery work conducted at the

Institute have fetched a number of highly prestigious global recognitions and

awards, including:

•

Pharma QbD Excellence Award 2012 by CPhI-Asia, Ahmadabad, India

•

AAPS QbD & Product Performance Award 2012, Chicago, USA

•

AAPS QbD & Product Performance Award 2013, San Antonio, USA

•

Outstanding QbD Scientist Award 2014 by Select Bio, Mumbai, India

•

Pharma QbD Performance Award 2015 by Stat-Ease, Minneapolis, USA

•

Scientist Par Excellence Award 2016 by Minitab, Coventry, UK

•

Global QbD Excellence Award 2019 by Shengjie, Shanghai, China

The unquenchable quest for knowledge has been continuing to reinforce our

humble contribution in this scientific domain and to serve the society thereof.

Fig. 18.14 Plasma concentration-time profile of mangiferin (Mgf) and its phospholipid-based

nanostructured lipidic carriers (PLCs-NLCs) in rat (mean  SEM; n ¼ 6)

340

B. Singh et al.